Generics, Infringement, Injunction, Inventive step, Netherlands, Pharmaceutical patent, Plausibility, Priority right, Validity
Dutch District Court upholds BMS’s apixaban patent
On 30 October 2024, the District Court of the Hague handed down two merits decisions on the widely litigated apixaban patent of Bristol-Myers Squibb (see here and here – Dutch language versions). EP 1 427 415 B1 (EP 415), which lapsed in 2022, and the corresponding supplementary protection certificates (SPCs) have been subject to litigation…